2007 Sales: $2.5 billion
Market share: 3.4%
What they have: Schering-Plough, which markets J&J's Remicade outside of the U.S, racked up $1.6 billion in sales in 2007. The company's pegylated interferon Hepatitis C injection Peg-Intron also brought in $911 million.
What to look for: Schering is partnered with J&J's Centocor on golimumab for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and ulcerative colitis. The company beefed up it's biotech pipeline with the $14 billion acquisiton of Organon Biosicences last year.